Conference Board fiscal outlook report ‘pretty optimistic for Manitoba'
However, Manitoba's situation is more favourable than other provinces — and long-term, the deficit will shrink, per the forecast.
'We are pretty optimistic for Manitoba,' said Richard Forbes, a Conference Board of Canada principal economist.
The non-profit released its annual provincial fiscal outlook this morning. A sluggish economy will be a drag on provincial government revenues across Canada, the paper reads.
Manitoba's net debt-to-GDP ratio may reach 33 per cent this year. It's high for the province but will be middling compared to other jurisdictions, the Conference Board predicted.
'A lot of the debt is still lingering from a few years ago,' Forbes said, citing spending during the COVID-19 pandemic. 'It could start to improve longer term as the province gets closer to a balanced budget.'
He doesn't expect a balanced budget in the next five years, but maybe within a decade. The Conference Board projects Manitoba's deficit to shrink to $540 million in 2029-30 from $1.2 billion in 2024.
Government revenues could rise by 6.3 per cent this year, partly because of the end of the NDP's gas tax holiday in January, the Conference Board said.
It believes revenue growth will moderate next year through 2030, with average annual gains of 2.9 per cent.
Manitoba has a young population, which is good for both the labour force and less stress on the health-care system, Forbes said.
He highlighted construction at the CentrePort Canada Rail Park. The 665-acre development lands inside the trimodal inland port, which connects businesses with highways, rail lines and air travel.
'Strong investments' in the Winnipeg-area park could boost corporate taxes and job creation, leading to consumer spending and income tax revenue, Forbes said.
The forecast doesn't account for a prolonged trade war with the United States. It assumes tariff action will peak during 2025's second quarter, with uncertainty subsiding later in the year.
Manitoba has tabbed up to $485 million in tariff relief for affected businesses and families, should the United States implement sweeping 25 per cent levies on imports. Such spending would push the deficit deeper, Forbes noted.
gabrielle.piche@winnipegfreepress.com
Gabrielle PichéReporter
Gabrielle Piché reports on business for the Free Press. She interned at the Free Press and worked for its sister outlet, Canstar Community News, before entering the business beat in 2021. Read more about Gabrielle.
Every piece of reporting Gabrielle produces is reviewed by an editing team before it is posted online or published in print — part of the Free Press's tradition, since 1872, of producing reliable independent journalism. Read more about Free Press's history and mandate, and learn how our newsroom operates.
Our newsroom depends on a growing audience of readers to power our journalism. If you are not a paid reader, please consider becoming a subscriber.
Our newsroom depends on its audience of readers to power our journalism. Thank you for your support.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
3 hours ago
Could U.S. tariffs drive up drug prices? Manitoba bioscience group says it's complicated, but possible
Medicine manufacturers across Canada are on edge with the looming threat of catastrophic tariffs on pharmaceutical exports to the U.S., experts say. Earlier this month, U.S. President Donald Trump threatened to impose tariffs as high as 200 per cent on pharmaceuticals exported to the United States. Howard Lutnick, Trump's secretary of commerce, said details about the pharmaceutical tariffs would come at the end of July. The uncertainty this created is starting to reveal itself as stock prices of major pharmaceutical manufacturing companies with operations in Canada — companies like Emergent Biosolutions and Bausch Health — have declined in recent days. If a 200 per cent tariff were to be put into place then I think [pharmaceutical manufacturers] would have to potentially reconsider whether it makes sense to manufacture in Canada, says Shawn Bugden, dean of the school of pharmacy at Memorial University. So what could the impact be in Canada? Given the tariff uncertainty, it's intensely complicated, says Bugden. According to government data, the pharmaceutical industry in Canada represents two per cent (new window) of global market share, and the manufacturing portion of it alone consists of an average of 35,000 jobs since 2019. Enlarge image (new window) Andrea Ladouceur, president and chief executive officer of the Bioscience Association of Manitoba, describes the pharmaceutical industry as the cornerstone of the province's economy. Photo: CBC / Justin Fraser In Manitoba, medicine is one of the leading industries, accounting for between 30-35 per cent of the medicine manufactured in Canada, seven per cent of the province's GDP, and roughly 14,000 jobs, according to Andrea Ladouceur, president of the Bioscience Association of Manitoba. The pharmaceutical industry is the cornerstone of the Manitoba economy, said Ladouceur. If being in Canada becomes unaffordable for them, these companies are connected to the global market and moving out of Canada is not off the table. The danger of these companies leaving is multifaceted. Not only would there be the major economic impact of a shrinking key industry, but we'd also lose the security of having some of the drug supply manufactured here in Canada, according to Bugden. The reliance on international trade for essential goods like medicines has proved risky in the past. During the COVID-19 pandemic, drug shortages (new window) in Canada were not uncommon. If pharmaceutical manufacturers move operations out of the country, it will likely make Canada even more reliant on global markets than they already are: with 70 per cent of drugs imported from foreign countries, 16 per cent of which is imported from the U.S., accounting for nearly $9 billion, according to Bugden. However, Budgen's main concern is that a sizable tariff, like the 200 per cent figure touted by Trump, would undermine Canada's price control mechanisms like the Patented Medicine Prices Review Board and the pan-Canadian Pharmaceutical Alliance — which he views as major assets to Canadians. The Patented Medicine Prices Review Board — established in 1987 but amended in 2019 — is meant to (new window) ensure that the prices of patented medicines sold in Canada are not excessive. The board reviews the price of drugs and medicine and conducts hearings which may result in orders to reduce prices to a non-excessive level, according to guidelines listed on their website. Shawn Bugden, dean of the school of pharmacy at Memorial University, says if Canadian pharmaceutical companies are hurt by tariffs on imports to the U.S., it could have an impact on the supply of some medicines in Canada. Photo: Submitted by Shawn Bugden Bugden says that as an unintended consequence, implementing such a substantial tariff would likely raise the cost of manufacturing drugs and medicine globally, in turn applying pressure on the review board to break their own rules and allow for higher-priced drugs. The Americans have been transparent, they say they have the highest drug prices in the world, we want to lower them, but we're not going to lower them, which is what they should do and they have the ability to do, we're instead going to try and make everybody else pay higher prices so that it allows our prices to go down, said Bugden. As things stand, many pharmaceutical companies are waiting to see what will happen. CBC News has reached out to several pharmaceutical companies in Manitoba, but none have wanted to comment given the uncertainty of the situation they're facing. Ladouceur says they're fearful that tariffs may force them to increase their prices. At the end of the day, any increase in cost will be passed on to the consumer, says Ladouceur. And so for these companies it is a very hard spot because they know it may put them out of reach for the consumer, and having medicines are key to having a healthy life and sometimes save a life, so they are really concerned their products will become unaffordable for those that need them most. Trump has said that there would be a period — a year, or a year and a half after a tariff would be imposed for companies to get their act together. In light of that, Bugden doesn't think the end consumer will be paying the price for at least a year. I don't think consumers need to worry about the prices changing tomorrow, said Bugden. Keep calm and carry on, don't think you need to run to the drug store and fill up your prescriptions. I'm confident in the institutions we have in Canada to do the best job possible to maintain pricing and accessibility for Canadians, said Bugden.
Global News
5 hours ago
- Global News
U.S. job market data shows weaker than expected results amid the trade war
U.S. employers added just 73,000 jobs last month and Labor Department revisions showed that hiring was much weaker than previously reported in May and June. The unemployment rate ticked up to 4.2 per cent. The deterioration in the job market is taking place with companies paralyzed by uncertainty over President Donald Trump's erratic trade policies. The Labor Department reported Friday that revisions shaved a stunning 258,000 jobs off May and June payrolls. The stock market tumbled on the news. The American job market is deteriorating — ever so slowly. It's not showing up as widespread layoffs. The unemployment rate is still low. It's subtler than that: New college graduates are struggling to break into the job market. The unemployment rate for college graduates 22 to 27 years old, reached 5.8 per cent in March, the highest, excluding the pandemic, since 2012, and far above the nationwide unemployment rate. Story continues below advertisement Many Americans are staying in their jobs, unwilling to start the job hunt, because they believe this is as good as it gets, and there is growing evidence that they're right: Few industries are actually hiring aggressively. The current situation is a sharp reversal from the hiring boom of just three years ago when desperate employers were handing out signing bonuses and introducing perks such as Fridays off, fertility benefits and even pet insurance to recruit and keep workers. 2:21 Trump vs. Powell: POTUS, Fed chair agree state of U.S. economy is strong, but disagree on interest rates When the Labor Department was expected to show that companies, government agencies and nonprofits collectively added 115,000 jobs last month, according to a survey of forecasters by the data firm FactSet. Get daily National news Get the day's top news, political, economic, and current affairs headlines, delivered to your inbox once a day. Sign up for daily National newsletter Sign Up By providing your email address, you have read and agree to Global News' Terms and Conditions and Privacy Policy That is not a bad number but its worse than last year, and even last month, when employers added 147,000 jobs. Employers added an average 130,000 jobs a month through June, down 23 per cent from last year's hiring and a whopping 68 per cent below the 2021-2023 average when the economy was bounding back from COVID-19 lockdowns. Story continues below advertisement Weighing on the job market are the lingering effects of higher interest rates that were used by the Federal Reserve to fight inflation; President Donald Trump's massive import taxes and the costs and uncertainty they are imposing on businesses; and an anticipated drop in foreign workers as the president's massive deportation plans move forward. 'The labor market is poised for a summer slowdown as businesses put hiring plans on hold but refrain from broad-based layoffs,' Gregory Daco, chief economist at EY-Parthenon wrote in a commentary this week. 'We see job growth slowing well below trend in the coming months.'' Still, most American workers enjoy an unusual level of job security. The unemployment rate is low at 4.1 per cent. The number of Americans applying for unemployment benefits — a proxy for layoffs — remains at healthy levels. But Adam Schickling, senior economist at Vanguard, cautions that 'a low unemployment rate and a muted pace of layoffs mask underlying weakness.'' In a commentary Tuesday, Schickling wrote that the health of the job market 'can be a matter of individual perspective…If you're a registered nurse, you may believe the job market's health to be excellent. The unemployment rate for experienced health care practitioners is currently below two per cent. If you're young and just entering the labor force or you're older and seeking to reenter it, prospects may seem bleak.'' Story continues below advertisement The rate of people quitting their jobs — a sign they're confident they can land something better — has fallen from the record heights of 2021 and 2022 and is now below where it stood before the pandemic. For one thing, hiring has become concentrated in a handful of industries. So far this year, for example, private U.S. employers have added 644,000 jobs. Of those, nearly 405,000 — or 63 per cent — were in just one of the Labor Department's industry categories: healthcare and social assistance, which spans everything from hospitals to daycare centers. As hiring has cooled over the past couple of years it's become harder for young people or those re-entering the workforce to find jobs, leading to longer job searches or spells of unemployment. The Labor Department said the number of discouraged workers, who believe no jobs are available for them, rose by 256,000 in June to 637,000. 'Historically, a decline in hiring has been accompanied by a swift rise in layoffs, a one-two punch that drives up the unemployment rate,' Schickling wrote in a commentary. 'Today's labor market is defying that pattern.'' One reason is that manufacturing companies, which tend to pull the trigger on layoffs quickly when economic conditions weaken, account for an ever-smaller share of American jobs. 'So there is simply less headcount to cut,'' he said. The bottom line: 'Firms are pulling back on hiring without shedding existing workers in significant numbers,'' Schickling said. 'The result is a labor market that is softening gradually, not collapsing.''
CBC
5 hours ago
- CBC
Canada Goose's summer apparel helps shift company from winter-brand perception
Canada Goose Holdings Inc. says its new lines of spring and summer clothing appear to be resonating with consumers, though the company posted a wider net loss in its latest quarter. Chief executive Dani Reiss said apparel such as T-shirts and polos have been some of the company's best sellers in recent months, helping the company change its perception that it's a winter-only brand. "The spring summer campaign brought a fresh energy to the brand, playful and relevant with a clear message: We do summer too," Reiss told analysts on a conference call Thursday. Rising temperatures and milder winters have pushed some retailers, including Canada Goose, to rethink their product mix. As a result, the company has been expanding its offerings to include lightweight puffers, sweaters, wind and rain wear, shoes and even eyewear in recent years. Despite the optimism from executives over its new product lines, the luxury parka maker reported a wider net loss of $125.5 million during its fiscal first-quarter, compared with a loss of $74 million during the same quarter last year. The loss was driven partly by higher spending on marketing campaigns and expanding its retail footprint. On an adjusted basis, it lost $1.29 per diluted share in the quarter, compared with an adjusted loss of 80 cents per diluted share last year. The Toronto-based company manufactures its core, down-filled products at seven facilities in Canada. That includes three in Winnipeg, three in the Greater Toronto Area, and one in Boisbriand, Que. Sales up, despite losses While its bottom line took a hit, the company says sales were actually higher. Revenue for the quarter totalled $107.8 million, up from $88.1 million a year ago. Direct-to-consumer revenue totalled $78.1 million, up 22.8 per cent from a year ago, while wholesale revenue rose 11.9 per cent to $17.9 million. Chief financial officer Neil Bowden said expanding the company's offerings over the last 12-15 months has borne fruit. "Things are working here," he told analysts. "That's why we've got confidence around the sustainability of it in spite of what is still a pretty choppy, tough consumer market." Consumer confidence has been hampered this year amid ongoing tariff threats from the U.S. and an economic slowdown, leading many shoppers to rein in their spending. Bowden said 75 per cent of the company's products are made in Canada and nearly all comply with the Canada-U.S.-Mexico Agreement, making them exempt from U.S. tariffs. But it is paying a "modestly higher tariff" on its European products. "We continue to monitor the ongoing developments as it relates to potential new U.S. tariffs on Canadian goods as well as potential second-order impacts on the consumer," Bowden said. Canada Goose shares were trading nearly nine per cent lower at $16.17 on the Toronto Stock Exchange as of midday Thursday.
